Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-23
    E.g., 2018-09-23

Articles

51716 items
12:00 AM, Mar 16, 2000  |  BC Extra | Clinical News

Eligix reports Phase I/II results

Eligix (Medford, Mass.) said that selective depletion of CD8+ lymphocytes from donor lymphocyte infusions may achieve remission in patients relapsing after bone marrow transplantation, with a reduction in the incidence of graft-versus-host disease (GvHD). In...
12:00 AM, Mar 16, 2000  |  BC Extra | Company News

Antisoma acquires cancer compound

Antisoma (LSE:ASM; EASD:ASOM) exercised its option to acquire Therex huHMFG1, a humanized monoclonal antibody to treat cancer, from the Imperial Cancer Research Fund. Therex is in Phase I studies to treat breast cancer....
12:00 AM, Mar 16, 2000  |  BC Extra | Clinical News

AVI BioPharma completes Phase I in restenosis

AVII said its Resten-NG antisense compound to prevent cardiovascular restenosis was safe in Phase I trials. Resten-NG targets c-myc, a gene responsible for initiating cell replication....
12:00 AM, Mar 16, 2000  |  BC Extra | Clinical News

ALLP's DSMB review

Alliance Pharmaceutical (ALLP) said that after reviewing data from 165 patients, a Data Safety Monitoring Board (DSMB) recommended continuation of the company's North American Phase II/III trial of LiquiVent liquid perflubron oxygen carrier to treat...
12:00 AM, Mar 16, 2000  |  BC Extra | Financial News

Nanogen raises $82.5 million

NGEN, which is developing its NanoChip biological test sample identification and analysis instrument, sold 1.5 million shares at $55 per share. The follow-on was underwritten by Warburg Dillon Read; Lehman Brothers; Dain Rauscher Wessels; Pacific...
12:00 AM, Mar 16, 2000  |  BC Extra | Company News

Cytotherapeutics settles three claims

CTII said it resolved differences with Genentech (DNA) and two Rhode Island agencies, Rhode Island Partnership for Science and Technology and Industrial Recreational Building Authority. The company said it was relieved of the obligation to...
12:00 AM, Mar 16, 2000  |  BC Extra | Clinical News

Emisphere starts Phase I trial with heparin

EMIS started a U.K. Phase I safety and tolerability study in healthy subjects of a solid oral dose of heparin to treat deep vein thrombosis and cardiovascular conditions. EMIS has a liquid form of heparin...
12:00 AM, Mar 16, 2000  |  BC Extra | Company News

Positive panel for PNU's Camptosar

The FDA's Oncologic Drugs Advisory Committee unanimously recommended for approval Camptosar irinotecan, a topoisomerase I inhibitor developed by Pharmacia & Upjohn (PNU), as a first-line treatment for metastatic colorectal cancer in combination with 5FU and...
12:00 AM, Mar 16, 2000  |  BC Extra | Financial News

Antex raises $15 million

Infectious disease play ANTX raised $15 million in a private placement....
12:00 AM, Mar 16, 2000  |  BC Extra | Clinical News

Cerus and Baxter complete Phase III enrollment

CERS and partner BAX completed enrollment of 100 patients in a European Phase III trial of their system to inactivate viruses, bacteria and other pathogens in platelet concentrates intended for transfusion. The system is based...

Pages